[Preoperative treatment with interleukin-2 in colorectal carcinoma]

G Chir. 1998 Apr;19(4):171-4.
[Article in Italian]

Abstract

Thirteen surgical patients affected by colorectal cancer have been evaluated to study the effectiveness of a short-term preoperative therapy with interleukin-2 (IL-2). Seven patients have been treated for three days before surgery with subcutaneous administration of IL-2 (9.000.000 U.I. b.i.d.). Six patients have been treated with placebo and have been considered as control group. All the patients have been operated upon 36-48 hours after the last administration of IL-2 or placebo. The assays of CD-3+, CD-4+, CD-8+ e CD-56+ lymphocytes, evaluated preoperatively and 7 days after the operation, have showed a postoperative increase of CD8+ and CD56+ and a decreased ratio of CD4+/CD8+. The results of this study, although not conclusive, suggest a positive antitumoral response in patients treated preoperatively with IL-2. Further studies could be performed to evaluate the survival after such a treatment.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adenocarcinoma / surgery*
  • Adult
  • Aged
  • Aged, 80 and over
  • CD3 Complex / immunology
  • CD4 Antigens / immunology
  • CD4-CD8 Ratio
  • CD56 Antigen / immunology
  • CD8 Antigens / immunology
  • Colorectal Neoplasms / immunology
  • Colorectal Neoplasms / surgery*
  • Female
  • Humans
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / therapeutic use*
  • Male
  • Middle Aged
  • Postoperative Period
  • Preoperative Care
  • Time Factors

Substances

  • CD3 Complex
  • CD4 Antigens
  • CD56 Antigen
  • CD8 Antigens
  • Interleukin-2